Industry context
Gilead Sciences Inc [GILD]
Last Updated 24 Jun 2026 @ 16:00 (Exchange is closed)
Last: $125.16
0.09%
-2.04 (↑)
GaG Algo Score™
v1.0
Short
-2.04 (↑)
Medium
-2.79 (↑)
Long
-2.22 (↑)
BUY
73.47%
return 8.71%
SELL
70.00%
return 17.68%
Line
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 6.27% | 6.27% | 0.60% |
| Loss % | -11.60% | -10.87% | 1.97% |
| Duration | 23.8d | 18d | 15.0d |
| Total Pivots Found | 6 |
| Gain/Loss Legs | 5 (2 Gain / 3 Loss) |
| Last Pivot | Bottom @ $121.48 on 2026-06-10 |
| Change since Last Pivot | $3.68 (3.03%) |
Next Pivot Prediction Last: $125.16
| Predicted Next Type | Top |
| Predicted Price (Avg) | $129.09 |
| Predicted Price (Median) | $129.09 |
| Predicted Price Range (~68%) | $128.36 - $129.82 |
| Change to Avg Target | $3.93 (3.14%) |
| Predicted Date (Avg) | 2026-07-03 |
| Predicted Date Range (~68%) | 2026-06-18 - 2026-07-18 |
| Basis | Based on 2 historical gains (Avg: 6.27%, Median: 6.27%, StdDev: 0.60%) and duration (Avg: 23.8 days, StdDev: 15.0 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Gilead Sciences Inc edges higher, up 0.09%.
Gilead Sciences Inc (GILD) stock price remained flat on Wednesday after the stock rose $0.110 (0.09%) from the previous session on normal volume. The stock held up slightly better than the falling NASDAQ (-0.43% down).(The stock has risen 3 days straight. This extended rally increases the chances of a price pullback soon) With 7.00M shares traded, volume yesterday reached $876.03M. This was 1.46M shares less than the prior day. Compared to the 10-day average of 8.74M shares, volume was less than the average.
Gilead Sciences Inc signals
There is no conclusive signals given from RSI. The price is below both moving averages, and the short-term average is below the long-term average, confirming a sustained down-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (-26.7%), medium- (-26.7%), and long-term (-26.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Gilead Sciences Inc Support & Resistance Levels
The stock is approaching the closest resistance level at $129.00. approximately $3.84 (3.07%) away. Approaching it. Breaking above this level could signal further upside where next resistance level will be found at $131. On a fall back there will be support at $112 The dis das resistance s1112 -
Gilead Sciences Inc Evaluation
- Short score: -2.04
- Medium score: -2.79
- Long score: -2.22
Ownership flow
GetAGraph InsiderPower
Transactions
447
Buy power
409.28M
Sell power
181.57M
Reliability
100/100
Buy / sell
2.25
Hist. corr.
0.67
Latest signal
Sell 2026-06-08
Officer 305
Executive 78
Director 64
2026-06-15
Mercier Johanna Officer
Sell 1 480
2026-06-15
Mercier Johanna Officer
Sell 1 070
2026-06-15
Mercier Johanna Officer
Sell 450
2026-06-15
Dickinson Andrew D Officer
Sell 3 000
2026-06-10
Berger Dietmar Officer
Buy 533
2026-06-10
Berger Dietmar Officer
Other 263
Relationship map
Correlation snapshot
<span style="background-color: lightgreen">Undervalued: <i class="arrow arrow-up"></i>0.83% <strong>$126.25</strong> paired level.</span>
Event context
Volume and dividends
Long volume corr.
-0.11
Short volume corr.
-0.95
Positioning pressure
Short interest pressure
Short interest
2.07%
Of outstanding shares
Short float
2.08%
Of tradable float
Days to cover
3.82
Short interest divided by average volume
Squeeze probability
3.10%
+11.20% change
Short positioning does not currently stand out as a dominant risk factor.
Updated 2026-05-29Income profile
Dividend profile
Last Dividend
$0.820
2026-06-15
Next Dividend
$0
N/A
Avg. yearly yield
2.84%
Quarterly
Total paid
$29.37
45 payments
Sustainability
0
low (50.00%)
Growth potential
5.00
Stable (0.00%)
Direction
1.937
Score based on dividend trend and payout behavior.
Yearly history
| Year | Dividend | Yield |
|---|---|---|
| - | $1.640 | 1.35% |
| - | $3.16 | 3.44% |
| - | $3.08 | 3.70% |
| - | $3.00 | 3.51% |
| - | $2.92 | 4.02% |
| - | $2.84 | 4.72% |
Recent payments
| Date | Dividend | Payment |
|---|---|---|
| 2026-06-15 | $0.820 | 2026-06-29 |
| 2026-03-13 | $0.820 | 2026-03-30 |
| 2025-12-15 | $0.790 | 2025-12-30 |
| 2025-09-15 | $0.790 | 2025-09-29 |
| 2025-06-13 | $0.790 | 2025-06-27 |
Earnings quality
Earnings history
Reported quarters
10
EPS beats
7
EPS misses
3
Avg. surprise
7.59%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-11-04 | - | - | - | - |
| Q2/2025 | 2025-08-14 | - | $1.990 | - | - |
| Q1/2025 | 2025-04-24 | $1.810 | $1.780 | 1.69% | 6.67B |
| Q4/2024 | 2025-02-11 | $1.900 | $1.740 | 9.20% | 7.57B |
| Q3/2024 | 2024-11-06 | $2.02 | $1.530 | 32.03% | 7.55B |
| Q2/2024 | 2024-08-08 | $2.01 | $1.610 | 24.84% | 6.95B |
| Q1/2024 | 2024-04-25 | $-1.320 | $-1.490 | 11.41% | 6.69B |
| Q4/2023 | 2024-02-06 | $1.720 | $1.760 | -2.27% | 7.12B |
Analyst view
Analyst targets
Consensus
$161.81
Median
$165.00
Low
$122.00
High
$180.00
Recent target updates
News flow
Latest company news
Market coverage
businesswire.com U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer Jun 24, 2026 zacks.com Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC Jun 24, 2026 seekingalpha.com Gilead Sciences: The Market Is Underestimating Its Growth Runway Jun 23, 2026 businesswire.com European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors Jun 23, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers General
Currency
USD
Gilead Sciences Inc is a global biopharmaceutical enterprise with operations spanning the United States Europe and numerous international markets Its core mission involves discovering developing and commercializing innovative medications to address critical health needs The companys extensive product portfolio encompasses treatments for a variety of severe conditions For HIVAIDS it supplies key therapies such as Biktarvy Genvoya Descovy Odefsey Truvada CompleraEviplera Stribild and Atripla In response to the 2019 coronavirus pandemic Gilead provides Veklury an injectable drug for intravenous administration Its offerings for liver diseases include Epclusa Harvoni Vosevi Vemlidy and Viread Furthermore Gilead assists patients battling hematological disorders various cancers and those undergoing cell therapy through products like Yescarta Tecartus Trodelvy and Zydelig Other specialized medicines include Letairis an oral drug for pulmonary arterial hypertension Ranexa also an oral medication for chronic angina and AmBisome a liposomal formulation designed to combat serious invasive fungal infections Gilead Sciences Inc actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline These include Arcus Biosciences Inc Pionyr Immunotherapeutics Inc Tizona Therapeutics Inc Tango Therapeutics Inc Jounce Therapeutics Inc Galapagos NV Janssen Sciences Ireland Unlimited Company Japan Tobacco Inc Gadeta BV BristolMyers Squibb Company Dragonfly Therapeutics Inc and Merck Co Inc The company was founded in 1987 and its corporate headquarters are situated in Foster City California
Navigation